

Supplementary Appendix

**Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients
With Moderate-to-Severe Chronic Kidney Disease-Associated Pruritus**

Authors:

James Fotheringham, PhD^{1,2}, Julien F Guest, PhD³, Joerg Latus, MD⁴, Edgar V. Lerma, MD⁵,
Isabelle Morin, MSc⁶, Thilo Schaufler, PhD⁶, Marco Soro, PhD⁷, Sonja Ständer, MD⁸, Steven
Zeig, MD⁹

1 School of Health and Related Research, University of Sheffield, Sheffield, UK

2 Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

3 Catalyst Consultants, Poole, UK

4 Robert-Bosch-Hospital, Stuttgart, Germany

*5 Department of Nephrology, Advocate Christ Medical Center, University of Illinois at Chicago,
Oak Lawn, Illinois, USA*

6 CSL Vifor, Glattbrugg, Switzerland

7 CSL Vifor, Rome, Italy

8 Münster, Germany

9 Pines Clinical Research, Pembroke Pines, Florida, USA

Corresponding author:

James Fotheringham, PhD

School of Health and Related Research, University of Sheffield, Sheffield, UK

Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

Email: j.fotheringham@sheffield.ac.uk

Phone: +44 114 222 4346

Supplementary table 1. Characteristics of the study population (safety population, N=222)

Characteristics	Safety population (N=222)
Mean \pm SD age (years) of patients	58.1 \pm 12.8
Male, n (%)	121 (54.5%)
Region, n (%)	
USA	203 (91.4%)
Europe	19 (8.6%)
Mean \pm SD dry body weight at baseline (kg)	86.6 \pm 23.5
Baseline anti-itch medication use, n (%)	70 (31.5%)
Mean \pm SD duration of pruritus (years) ^a	3.89 \pm 3.31
Mean \pm SD duration since diagnosis of ESRD (years) ^b	5.87 \pm 4.69
Mean \pm SD duration on chronic haemodialysis (years) ^c	5.42 \pm 4.41
Mean \pm SD duration since diagnosis of CKD (years) ^d	8.51 \pm 6.88
Aetiology of chronic kidney disease, n (%) ^e	
Hypertension	135 (60.8%)
Diabetes	110 (49.5%)
Other	25 (11.3%)
Glomerulonephritis	11 (5.0%)
Large vessel disease	4 (1.8%)
Urologic	3 (1.4%)
Cystic	2 (0.9%)
Pyelonephritis	2 (0.9%)

Unknown	2 (0.9%)
Interstitial nephritis	1 (0.5%)
Nephrotic syndrome	1 (0.5%)
Tumours	1 (0.5%)
Vasculitis	1 (0.5%)

Dialysis type at screening, n (%)

Haemodialysis	216 (97.3%)
Haemodiafiltration	6 (2.7%)

CKD, chronic kidney disease; ESRD, end-stage renal disease; SD, standard deviation

Vital signs baseline was defined as the last measurement taken on or prior to the first day of dosing.

^aDuration of pruritus in years was calculated as (date of the screening visit – the start date of the pruritus + 1)/365.25.

^bYears since diagnosis of ESRD was calculated as (date of the screening visit – first date of ESRD diagnosis + 1)/365.25.

^cYears on chronic haemodialysis was calculated as (date of the screening visit – date of first chronic haemodialysis + 1)/365.25.

^dYears since diagnosis of CKD was calculated as (date of the screening visit – first date of CKD + 1)/365.25.

^eMore than one item may have been checked and thus the sum can be over 100%.

^{||}Nephrotic syndrome may present in several different kidney diseases.